Randomized clinical trial: Macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome

American Journal of Gastroenterology

Volumn 108, Issue 9, 2013, Pages 1508-1515

  Chapman, R W ^a   Stanghellini, V ^b   Geraint, M ^c   Halphen, M ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Keaton House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL 3350; PLACEBO;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; CONSTIPATION; DOUBLE-BLIND METHOD; ELECTROLYTES; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84883744403     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.197     Document Type: Article

References (36)

1. Longstreth GF , Th ompson WG , Chey WD et al. Functional bowel disorders. Gastroenterology 2006 ; 130 : 1480-91.
2. Ruepert L , Quartero AO , de Wit NJ et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev , 2011; (8): CD003460.
3. Grundmann O , Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010 ; 25 : 691-9.
4. NICE 2008. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. Clinical Guideline 61. February 2008.
5. Shah E , Kim S , Chong K et al. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med 2012 ; 125 : 381-93.
6. American College of Gastroenterology Task Force on Irritable Bowel Syndrome, Brandt LJ , Chey WD et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009 ; 104 (Suppl 1) : S1-S35.
7. Bijkerk CJ , Muris JW , Knottnerus JA et al. Systematic review: the role of diff erent types of fi bre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004 ; 19 : 245-51.
8. Lacy BE , Weiser K , De Lee R. The treatment of irritable bowel syndrome. Therap Adv Gastroenterol 2009 ; 2 : 221-38.
9. Attar A , L é mann M , Ferguson A et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999 ; 44 : 226-30.
10. Cleveland MV , Flavin DP , Ruben RA et al. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J 2001 ; 94 : 478-81.
11. DiPalma JA , Cleveland MV , McGowan J et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol 2007 ; 102 : 1436-41.
12. Lee-Robichaud H , Th omas K , Morgan J et al. Lactulose versus polyethylene clycol for chronic constipation. Cochrane Database Syst Rev 2010 (7): CD007570.
13. NICE 2010. Constipation in children and young people: diagnosis and management of idiopathic childhood constipation in primary and secondary care. Clinical Guideline May 2010.
14. Th omson MA , Jenkins HR , Bisset WM et al. Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study. Arch Dis Child 2007 ; 92 : 996-1000.
15. Khoshoo V , Armstead C , Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006 ; 23 : 191-6.
16. Awad RA , Camacho S. A randomized, double-blind, placebo-controlled trial of polyethylene glycol Effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis 2010 ; 12 : 1131-8.
17. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 ; 130 : 1377-90.
18. Lewis SJ , Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997 ; 32 : 920-4.
19. L é mann M , Chaussade S , Flourie S et al. The effi cacy of low dose polyethylene glycol (PEG) 3350 (Movicol ® ) in idiopathic constipation; double blind crossover study against placebo. Gastroenterol Clin Biol 1994 ; 18 : B256.
20. EMEA CPMP (The European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products) CPMP/EWP/785/97. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. March 2003.
21. Corazziari E , Badiali D , Bazzocchi G et al. Long term effi cacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000 ; 46 : 522-6.
22. Drossman DA , Morris CB , Hu Y et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defi ning an alternator. Gastroenterology 2005 ; 128 : 580-9.
23. Engsbro AL , Simren M , Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classifi cation. Aliment Pharmacol Ther 2012 ; 35 : 350-9.
24. Lembo A , Camilleri M. Chronic constipation. N Engl J Med. 2003 ; 349 : 1360-8.
25. Pashankar DS , Loening-Baucke V , Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003 ; 157 : 661-4.
26. Parvin A , Farzaneh A , Ali HN. A comparative trial: the safety and clinical effi cacy of PEG 3350 and liquid paraffi n in management of chronic functional constipation in children. Int J Clin Med 2012 ; 3 : 383-6.
27. Voskuijl W , de Lorijn F , Verwijs W et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004 ; 53 : 1590-4.
28. DiPalma JA , DeRidder PH , Orlando RC et al. A randomized, placebocontrolled, multicenter study of the safety and effi cacy of a new polyethylene glycol laxative. Am J Gastroenterol 2000 ; 95 : 446-50.
29. Electronic Medicines Compendium (eMC). www.medicines.org.uk/emc (accessed 09 August 12).
30. Norgine Ltd. Movicol Summary of Product Characteristics. May 2011. http://www.medicines.org.uk/emc/medicine/1244/SPC/Movicol+13.8g+ sachet,+powder+for+oral+solution/(accessed 16 July 2012).
31. Patel SM , Lembo AJ. Constipation. In: Feldman M, Friedman LS, Brandt LJ (eds). Sleisenger and Fordtrans's Gastrointestinal and Liver Disease-Pathophysiology/Diagnosis/Management , 8Thedn. Saunders: Philadelphia , 2006 pp 221-53.
32. Wang HJ , Liang XM , Yu ZL et al. A randomised, controlled comparison of low-dose polyethylene glycol 3350 plus electrolytes with ispaghula husk in the treatment of adults with chronic functional constipation. Clin Drug Investig 2004 ; 24 : 569-76.
33. Chiou E , Nurko S. Management of functional abdominal pain and irritable bowel syndrome in children and adolescents. Expert Rev Gastroenterol Hepatol 2010 ; 4 : 293-304.
34. Lunsford TN , Harris LA. Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health 2010 ; 2 : 361-74.
35. Chey WD , Maneerattaporn M , Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011 ; 5 : 253-66.
36. Lee N , Wald A. Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation. Core Evid 2012 ; 7 : 39-47.